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Abstract: Post-surgical adhesions are internal scar tissue and a major health and economic burden.
Adhesions affect and involve the peritoneal lining of the abdominal cavity, which consists of a contin-
uous mesothelial covering of the cavity wall and majority of internal organs. Our understanding of
the full pathophysiology of adhesion formation is limited by the fact that the mechanisms regulating
normal serosal repair and regeneration of the mesothelial layer are still being elucidated. Emerging
evidence suggests that mesothelial cells do not simply form a passive barrier but perform a wide
range of important regulatory functions including maintaining a healthy peritoneal homeostasis as
well as orchestrating events leading to normal repair or pathological outcomes following injury. Here,
we summarise recent advances in our understanding of serosal repair and adhesion formation with
an emphasis on molecular mechanisms and novel gene expression signatures associated with these
processes. We discuss changes in mesothelial biomolecular marker expression during peritoneal
development, which may help, in part, to explain findings in adults from lineage tracing studies using
experimental adhesion models. Lastly, we highlight examples of where local tissue specialisation
may determine a particular response of peritoneal cells to injury.
Keywords: peritoneum; mesothelium; serosal repair; post-surgical adhesions; molecular signa-
tures; biomarkers
1. Introduction
Adhesions are bands of scar tissue connecting opposing organs together or to the inner
abdominal cavity wall. They can take several forms, ranging from thin translucent films
to thick, organised cords; however, histologically they are well vascularised, innervated
with varying degrees of adipose tissue, dense collagen foci and inflammatory cells [1–3].
Although surgery is the main inducer of adhesions, they can also occur after inflammatory
episodes such as peritonitis and endometriosis. Many patients will be clinically asymp-
tomatic post-surgery; however, others will experience high morbidity, significant health
issues, and possible hospitalisation for adhesion-related complications including bowel
obstruction, female infertility, and chronic pelvic pain as well as difficulties with any repeat
surgery [4]. It is proposed that adhesions form in 79–90% of patients who have open
abdominal or pelvic surgery [5,6]. The Surgical and Clinical Adhesions Research (SCAR)
group performed the first large retrospective cohort study of over 21,000 patients who
underwent open abdominal or pelvic surgery [7]. They found that 5.7% of re-admissions
were directly related to adhesions with nearly a quarter of these being in the first year after
surgery [7]. Several follow-on studies have since confirmed the impact of adhesions and
related complications on the number of hospital re-admissions [8,9]. Of note, although
minimally invasive laparoscopy reduces the incidence of adhesion-related readmissions,
overall adhesions still represent a significant burden post-surgery and further assessment
suggests that the proportion of re-admissions directly related to adhesions post-surgery
may have been underestimated in initial studies [10]. Furthermore, an increase in the
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ageing population and associated rise in metabolic disorders, such as diabetes and obesity,
is proposed to be related with a higher risk of post-operative adhesion development in such
patient cohorts [11]. Subsequently, adhesion associated complications impose a substantial
economic burden on health systems with costs likely to increase in the future [12]. Adhe-
siolysis is a common surgical procedure to remove adhesions in later surgery; however,
it carries a risk of bowel perforation [13], and adhesions are likely to reform at a later
date [14], and so it may not be an ideal long-term therapeutic solution.
Small bowel obstruction following laparotomy constitutes between 0.9–2% of all
general surgical admissions [15], and data suggests that a high percentage of these are
due to adhesions [16]. A further major complication of adhesions is female infertility
where bands of scar tissue distort reproductive organs so preventing normal movement
of the oocyte [17]. Data has shown that women with pelvic adhesions who underwent
adhesiolysis had a greater pregnancy success rate compared to women who were treated
non-surgically [18]. Additional findings suggest an association between patients with
peritoneal adhesions and chronic pelvic pain [14]. Indeed this may be an under-estimated
problem due to difficulties in monitoring pain and the relatively rapid re-formation of
adhesions after lysis and return of pain symptoms [19,20]. Furthermore, the finding that
adhesions contain sensory nerves [21], and that laparoscopic manipulation of adhesions in
conscious patients can elicit pain, adds further strength to a possible relationship between
adhesions and chronic pain [22].
Preventative measures to reduce adhesion formation are limited but atraumatic surgi-
cal technique still represents the gold standard in combination with avoiding unnecessary
handling of the viscera, meticulous haemostasis, and avoiding air drying of exposed tissues
and cauterisation where necessary [23]. Preventative therapies include physical barriers
that can be grouped as fluids, films and gels, and which work by keeping damaged ab-
dominal serosa separated during the healing period. However, many of these barriers
have limitations, in particular, in minimally invasive laparoscopic surgery, and uptake by
surgeons is relatively low [24]. New barriers are being developed and mainly involve fabri-
cation of natural and synthetic hydrogels (reviewed in [4]). However, preventing as many
adhesions forming as possible may not necessarily relate to a proportional reduction in the
risk of adhesion-related complications. For instance, it has been noted that extensive dense
adhesions spanning many organs may not necessarily be linked with any complications
whereas a single adhesive band could cause life-threatening bowel obstruction [25].
The combination of unmet clinical need and high health costs demonstrates the
importance of pursuing a more detailed understanding of how adhesions develop in order
to find improved preventative strategies to reduce their incidence. While the focus of this
review is limited to the peritoneum, adhesions also occur in the other two body cavities,
pleural or pericardial, and so common mechanisms may be involved. Furthermore, as
the majority of adhesions occur post-operatively, the consequences of surgically related
injury will be the emphasis of this review; however, there is likely overlap with other
damage inducing scenarios involving chronic inflammation, infection, peritoneal dialysis,
and ischaemia.
2. Serosal Repair and Adhesion Formation
Adhesions are generally viewed as a sequel to the normal repair process following
an injury to the peritoneum. However, the reasons why adhesions occur as opposed to
normal repair and serosal regeneration are still being elucidated.
2.1. Serosal Repair
Peritoneum is an extensive thin layer of serosa covering most internal abdomi-
nal/pelvic organs and mesentery (visceral peritoneum) and the inner body wall (parietal
peritoneum), making it the largest serous membrane found in humans [26]. It consists of a
surface mesothelial cell layer attached to a basal lamina overlying a vascularised subme-
sothelial stroma consisting of mesenchymal cells including fibroblasts, endothelial cells,
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and immune cells. A limited amount of peritoneal fluid or plasma transudate coats the
peritoneal surface [27]. This layer is essential for maintaining intra-abdominal homeostatic
equilibrium and acts as a protective barrier and support for organs. Mesothelial cells show
a complex organization displaying apical-basal polarity, intercellular junctions, and apical
microvilli with the occasional cilia [28]. Interestingly, mesothelial cells in the adult peri-
toneum express both intermediate filaments of epithelial (cytokeratin) and mesenchymal
(vimentin) characteristics [29]. Furthermore, cuboidal and squamous phenotypes have been
observed depending on anatomical location and state of activation [30–33]. A glycocalyx
produced apically consists of a carbohydrate-rich layer of proteoglycans and glycosamino-
glycans which in combination with surfactant aids in lubricating serosal surfaces to reduce
friction and enable smooth gliding of organs within the cavity [34,35]. Junctional complexes
between cells include tight, adherens and gap junctions and desmosomes. Gap junctions
act predominately as aqueous intracellular channels while adherens give structural support
and tight junctions provide semipermeable properties regulating water, ions, and other
solute diffusion [36]. These specialised cells perform a multitude of functions including
selective fluid and cell transport, regulation of extracellular matrix (ECM) turnover through
production of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) as well as
generation of procoagulant and fibrinolytic activity [37]. Furthermore, mesothelial cells are
integral to immune induction, modulation, and inhibition and can phagocytose pathogens
and present antigens to T cells [38]. Mesothelium is often overlooked and thought of as
just a barrier, but much evidence now suggests that it is physiologically active responding
to changes in the local environment and in fact determines the outcome of injury and/or
disease related events in serosal cavities [37].
Mild injury to the peritoneum induces the release of damage-associated molecular
patterns (DAMPs) from dying cells causing a rapid recruitment of innate immune cells. In
particular, a strong influx of neutrophils and macrophages populate the damaged serosa
within a few hours [39]. In response to a sterile injury in the liver of mice, a population
of fully mature peritoneal cavity macrophages expressing the zinc finger-containing tran-
scription factor GATA-binding protein 6 (GATA6; named after the ‘A/TGATAA/G’ DNA
consensus motif in the regulatory regions of target genes to which all GATA family mem-
bers bind) was shown to swiftly invade into areas of damage via direct recruitment across
the mesothelium [40]. Such invasion was dependent on CD44 binding of macrophages
to exposed hyaluronan at the injury site and ATP production providing DAMP signals
from necrotic cells. Similar to other damaged epithelia, mesothelial cells at the wound edge
initially lose apical-basal polarity, detach from the basal lamina and each other through
degradation of junctional complexes, and start to migrate into the wound [41,42]. Indeed,
an increase in mesothelial cell proliferation at the wound edge has been documented [43].
Of interest, mesothelial cells are also proposed to detach from adjacent surfaces post-injury,
free-float in serosal fluid, and implant and adhere onto denuded sites where they form
islands of cells that connect together to complete re-epithelialisation [44,45]. Small and
large wounds are proposed to re-epithelialise in the same timeframe suggesting that at
least a combination of inward migration of mesothelial cells from the wound edge and
incorporation of free-floating cells is involved in the repair process. However, additional
sources of new repair cells have been put forward such as mesenchymal precursors [46]
and macrophages [47]. Further evidence suggests that surgical injury to the mesothelial
layer induces recruitment of a circulating progenitor cell population derived from the bone
marrow [48]. These progenitor cells express mesothelial markers such as the cell surface
glycoprotein, mesothelin, and cytokeratins and can free-float and populate denuded serosa
but only act as a temporary covering that lasts up to a month. It is proposed that these cells
are the same or similar to those found by others and known as tissue repair cells [49], post-
surgical cells [50], and circulating cells of hemopoietic origin [51]. It is unlikely that just one
of these events is the sole mechanism by which mesothelial-like cells repopulate a denuded
serosal wound, but rather several of these processes contribute to epithelial regeneration.
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Strong evidence also supports the notion that mesothelial cells undergo a process of
epithelial-mesenchymal transition (EMT), known as mesothelial-mesenchymal transition
(MMT), following serosal damage [44,52,53]. This phenomenon has been a particular focus
of the peritoneal dialysis field and thought to underlie the development of peritoneal
thickening and fibrosis associated with repeated injury of the mesothelial layer [54]. Initial
stages of MMT involve loss of apical-basolateral polarity combined with a reduction of
epithelial cytoskeletal markers and cell-cell and cell-basal lamina detachment. Transitioned
cells take on a motile phenotype and display an increase in mesenchymal cytoskeletal
markers eventually becoming invasive and fully transitioned into alpha-smooth muscle
actin (αSMA)- positive myofibroblasts [55]. The role of TGF-β1 in promoting MMT is
well-documented [56–58] and several key signalling pathways associated with TGF-β,
IL-1β, angiotensin II, HIF-1α, and pleiotrophin have been implicated [59–63]. By inducible
genetic fate mapping, Chen and colleagues reported that sodium hypochlorite injured
serosa is repaired by mesothelial cells positive for Wilms’ tumour protein 1 (WT1); however,
they questioned the role of MMT in mediating peritoneal fibrosis [64]. Although both
mesothelial cells and subserosal fibroblasts expressed αSMA in culture, only subserosal
fibroblasts expressed this myofibroblast marker after chemically induced injury or overex-
pression of TGF-β1 in vivo. Furthermore, only subserosal fibroblasts but not mesothelial
cells expressed the PDGF receptor, and inhibition of this receptor reduced peritoneal fi-
brosis but not re-mesothelialisation [64]. We purified rat omental mesothelial cells using
an antibody against HBME1 which is expressed on mesothelial cell microvilli and found
these cells to be 90% positive for WT1, and expressed transcripts of epithelial markers, tight
junction protein 1 (Tjp1, also known as ZO1), mesothelin, uroplakin 3b, and podoplanin but
also the mesenchymal transcript, vimentin [65], as shown by others [29]. Interestingly, TGF-
β1-treated mesothelial cells displayed a distinctive MMT signature, with downregulation
of molecules involved in insulin-like growth factor (IGF) and bone morphogenic protein
(BMP) signalling and upregulation of transcription factor, Sox9 and ECM glycoproteins,
tenascin C and N [65]. Genetic lineage tracing of WT1-expressing mesothelial cells after
surgical injury in mice confirmed that mesothelial cells adopt a mesenchymal phenotype
and migrate into the subserosa. Addition of BMP4 prevented this transition possibly
highlighting a new therapeutic strategy to limit MMT and peritoneal fibrosis. A hallmark
of MMT is considered the downregulation of E-cadherin and destabilisation of adherens
junctions [66]; however, several groups have found low expression of this epithelial cell-cell
junction protein in mesothelial cells, both in rodents and humans [65,67,68]. Variations in
the state of mesothelial cell activation, possibly dependent on whether in vitro or in vivo
and/or source as well as type of stimulation, may determine a heterogeneity in the MMT
gene expression signature found.
2.2. Mechanism of Adhesion Formation
Coagulation involving platelet aggregation in combination with plasma protein de-
position is part of the normal repair process. However, when this provisional fibrin-rich
matrix is not cleared in a timely manner, it acts as a scaffold for tissue repair cell ingrowth
and leads to increased collagen deposition and fibrosis [69]. A major contributor to ad-
hesion development after surgical damage is the dysregulation of fibrinolysis in which
levels of the activated fibrinolytic protease, plasmin, determine the balance between fibrin
deposition and degradation. Plasminogen activator inhibitor-1 (PAI-1) is one of the main
inhibitors of fibrinolysis whereas plasminogen activators (PAs) activate plasminogen and
mediate fibrinolysis. Post-surgery, PAI-1 levels have been found to increase, and PA levels
decrease, leading to delayed fibrin matrix dissolution [70]. Consequently, fibrin-rich bridges
that form between closely opposed damaged serosa may persist longer than necessary,
allowing an influx of repair cells. With subsequent vascularisation and ECM deposition,
these fragile structures become permanent features, often within a week of surgery [71,72].
Presence of foreign body material, such as sutures or mesh implants, and/or infection will
exacerbate this imbalance in fibrinolysis resulting in excessive fibrin deposition and an
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increased risk of adhesion development. Many studies have demonstrated that reducing
tissue plasminogen activator (tPA) or increasing PAI-1 results in increased adhesion for-
mation whereas increasing tPA and decreasing PAI-1 activity induces less adhesions to
form [73–76]. Of relevance, Hellebrekers and colleagues found that in patients undergoing
pelvic surgery, preoperative high PAI-1 and low tPA levels were positively correlated with
extent of postoperative adhesion development [77].
The degree of inflammation is also integral to the repair outcome post-surgery. Sim-
ilar events to those observed following mild serosal injury occur, with an early influx
of inflammatory cells producing a plethora of growth factors and cytokines to induce
subsequent granulation tissue formation and re-epithelialisation. Interestingly, cells of the
adaptive immune system have been found to be essential regulators of post-surgical adhe-
sion formation and dependent on CD28 T cell costimulatory and inhibitory programmed
death-1 pathways [78,79]. Tsai and colleagues demonstrated that following a surgical injury,
mesothelial cells directly mediate an influx of neutrophils and monocytes by upregulating
the expression of cytokines such as CXCL1 and MCP-1 [80]. Neutrophils subsequently
underwent cell senescence and formed neutrophil extracellular traps (NETosis) whereas
tissue resident macrophages disappeared suggesting a change in inflammatory cell kinetics
during adhesion formation [80]. Several growth factors and cytokines have been implicated
in adhesion formation including VEGF, IL-6, IL-17, and IFN-γ. Again, the importance of
TGF-β in post-operative adhesion development has been extensively highlighted from
in vivo studies and it is well known that TGF-β1 upregulates PAI-1 production and is a
major inducer of collagen deposition. Indeed, mice with only one copy of the Tgfb1 gene
develop less extensive adhesions [81] and neutralisation of TGF-β1 reduced the extent of
adhesions after surgery [82,83]. Furthermore, patients with adhesions display almost dou-
ble the amount of active peritoneal TGF-β1 compared with patients without adhesions [84],
and this was associated with a reduced fibrinolytic activity. Torres and colleagues also
found that plasma levels of preoperative TGF-β and C-reactive protein and Neutrophil-to-
Lymphocyte ratio may be robust predictors of peritoneal adhesion formation in patients
who had undergone previous surgery [85]. Intriguingly, the ratio of TGF-β3, another
TGF-β isoform, to TGF-β1, and the spatial distribution of these two isoforms, has been
found to be important in determining whether fibrous adhesions form, with high levels
of TGF-β3 found to be anti-fibrotic [86]. In addition, co-localisation of the isoforms with
either membrane or soluble TGF-β receptor, betaglycan, is thought to regulate adhesion
development and it is proposed that different serosal tissue may predispose to forming
adhesions based on their basal expression of these factors [87].
Over the last few years, there has been little advance in the development of new anti-
adhesion therapies progressing into standard clinical practice. A multitude of anti-adhesion
drugs have been investigated in vivo, targeting key events in adhesion pathogenesis such as
coagulation/fibrinolysis, inflammation, collagen deposition, and hypoxia [4]. Unresolved
issues include side effects such as bleeding, half-life of drugs in the peritoneal cavity, their
localisation at the site of adhesion formation and disruption of normal wound healing at
incision sites. Another approach is to develop better barrier materials that have specific
properties such as: (i) biocompatible with low immunogenicity, (ii) biodegradable, (iii) easy
to administer, and (iv) remaining in place over the critical stages of adhesion formation
(3–5 days post-surgery). Currently available solutions, such as films and gels, are classed
as physical barriers that mechanically keep serosa apart. To successfully drive therapeutic
applications forward, there is a need to develop tailored barriers with properties that can
regulate molecular pathways and cell behaviour, therefore modulating adhesion formation.
The formulation of such applications is an exciting future prospect that requires a multi-
disciplinary approach, bringing together cell biologists, pharmacologists, and material
scientists. Drugs incorporated into hydrogels are appearing as a favourable option, as they
act as physical barriers and can be fabricated to deliver bioactive agents in a controlled
and sustained manner to affect adhesion formation [4]. Lastly, cell sheets of autologous
mesothelial cells and peritoneal patches have also been assessed as anti-adhesion strategies
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in animal models with some promising results [88,89]. However, while a biopharmaceutical
and cellular therapeutic route to regulate adhesion development is desirable, the role of
peritoneal and other cells in post-surgical fibrinogenic events needs to be elucidated.
2.3. Cellular Contribution to Adhesions
Lineage tracing studies in mice have shown that several major peritoneal cell types
contribute to adhesion formation including fibroblasts, macrophages, and mesothelial cells.
Fibroblasts, specifically myofibroblasts, are known to populate adhesion tissue derived
from patients [1]. Rout and colleagues found that fibroblasts isolated from adhesions and
grown in culture displayed a different expression profile compared with those grown from
healthy peritoneum, with genes involved in fibroblast activation and fibrogenesis were
upregulated in adhesion-derived fibroblasts [90]. Moreover, targeting downstream, fibrosis-
associated pathways such as Mitogen-activated protein kinase kinase (MEK) demonstrated
a reduction in adhesion formation in mice [91]. Of importance, Foster et al. analysed
adhesions from patients and mouse models to elucidate the heterogeneity and source
of fibrogenic cells. Fibroblasts within adhesions were found to express platelet derived
growth factor receptor alpha (PDGFRA), a transmembrane receptor tyrosine kinase, as
well as fibroblast markers, such as αSMA, vimentin, and collagen 1 (COL1) [92]. In murine
ischaemic tissue-induced adhesions, fibroblasts expressed JUN (proto-oncogene, named
after viral homolog v-jun in avian sarcoma virus 17), which is a transcriptional master
regulator of fibrogenesis, and a portion of these cells were also positive for the mesothelial
marker mesothelin (MSLN). The authors excluded mesothelial cells as a major source of
the adhesion fibroblasts using mesothelial (WT1)-specific lineage tracing in combination
with the adhesion induction. Instead, they determined that tissue-resident, progenitor-type
fibroblasts that proliferate polyclonally were the main contributor. Such repair cells were
mainly derived from the visceral rather than parietal peritoneum. Using single cell RNA
sequencing, heterogeneity between PDGFRA+ adhesion fibroblasts at early timepoints
post-surgery was identified, since three transcriptionally distinct fibroblast clusters were
found in mouse adhesion samples whereas four were present in human samples. Analysis
of these clusters in relation to their timepoints revealed that early JUN activation promoted
a profibrotic state as reflected in the expression profiles. Moreover, inhibition of the
highly expressed Jun/Jak/Stat pathway was found to reduce adhesion formation and was
proposed as a novel preventative strategy [92].
The role of macrophages in adhesion formation is somewhat controversial with some
groups finding a reduction in adhesions in macrophage depleted mice [93], while others
reporting an increase in adhesions when macrophages were depleted through chemi-
cal means [75]. Furthermore, mesenteric mesothelial cells are thought to transition to
a macrophage phenotype post-injury [94] so adding to this complexity. Using a mouse
post-operative adhesion model, Hoshino et al. found that macrophages formed aggregates
at sites where of adhesion development [95]. This event was regulated by CCR8, a receptor
specifically upregulated on peritoneal cavity macrophages but not bone-marrow derived
macrophages. Using macrophage CCR8 deficient mice or an inhibitor of its ligand, CCL1,
they demonstrated a significant reduction in the incidence of adhesions [95]. Importantly,
CCL1 is produced by mesothelial cells and macrophages and known to upregulate ex-
pression of PAI-1 resulting in reduced fibrinolysis. Furthermore, inhibition of PAI-1 is
found to reduce F4/80+ macrophage influx and inhibit adhesion formation [75]. Recently,
Zindel et al. showed that following severe ischaemic injury, GATA6+ peritoneal cavity
macrophages form superaggregates between tissues that act as precursors to adhesions [96].
Mesothelial cells have been proposed as another important source of fibrogenic cells
that mediate adhesion formation through a process of MMT. Using human adhesion sam-
ples, Foster and colleagues demonstrated that a small portion of JUN+ fibroblasts also
expressed the mesothelial marker MSLN and the EMT pathway was one of the most
significantly upregulated molecular profiles in cultured adhesion fibroblasts [92]. San-
doval and colleagues also analysed human adhesions and showed co-localisation of the
Biomolecules 2021, 11, 692 7 of 17
epithelial marker, cytokeratin and the mesenchymal marker, αSMA, in spindle-like cells
in the subserosa strongly implicating that mesothelial cells had transitioned to become
myofibroblasts [97], a feature commonly found in biopsy samples from peritoneal dialysis
patients [54]. Using the mouse ischaemic -induced adhesion model, they also demon-
strated that mature adhesions contained a sub-population of subserosal cells expressing
both myofibroblast, such as αSMA, and mesothelial/epithelial markers, such as WT1 and
cytokeratin [97]. Recently, Tsai and colleagues demonstrated that inhibition of mesothelin,
reduced adhesion formation after ischaemic injury by using clonal analysis and lineage
tracing [98]. Furthermore, they showed that the injured surface mesothelium upregulated
HIF1α signalling, and that blocking this pathway reduced adhesion formation. Similar
markers and signalling molecules were also found in human adhesions [98]. In addi-
tion, Strippoli and colleagues discovered a role for mechanical stress in inducing MMT
in mesothelial cells which was driven by Caveolin1 and yes-associated protein (YAP1),
suggesting an interplay between biochemical and biomechanical signalling in the devel-
opment of adhesions [99]. Of relevance, fibrin has also been identified as an inducer
of MMT [100] and so the combination of many factors post-surgery is likely to create a
favourable local environment to trigger adhesion development. The current understanding
of cellular contributions to adhesion formation in response to surgical injury is summarised
in Figure 1.
Figure 1. Schematic demonstrating the different cellular contributions to adhesion formation.
3. The Developmental Origin of Mesothelium
Strong evidence supports the notion that mesothelial cells are directly incorporated
into and play active roles in developing adhesions in the adult. It is therefore important to
consider whether a reactivation of the embryonic MMT program occurs with reappearance
of certain differentiation markers and developmental signalling pathways. In order to
further understand alterations in phenotype and their molecular regulation, in conjunction
with molecular expression profiles of mesothelial cells during adhesion formation, changes
in key mesothelial cell markers that occur normally during development are discussed.
Mesothelia in the three serosal cavities (pericardial, pleural, and peritoneal) have
their origin in mesodermal tissues that are formed during gastrulation in the embryo. The
peritoneal coelomic cavity is formed from the lateral plate mesoderm under influence
of ectodermal factors [101]. Previous studies in the chick have demonstrated that the
mesothelium in the peritoneal cavity arises from resident progenitor cells, in contrast to
the pro-epicardium-derived epicardium of the heart [102]. The formation of the mesothe-
lium that covers the intestine was tracked using GFP-expressing plasmid or retrovirus
electroporated into splanchnic mesenchymal tissues before the arrival of a mesothelium,
and these labelled cells were found to give rise to the epithelial mesothelial lining. Whether
this developmental process takes place similarly in the mouse has yet to be demonstrated.
Intriguingly, events described by Winters and colleagues [102] suggest that a transition
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process where splanchnic mesenchymal cells differentiate into mesothelial cells plays a
role in the embryonic development of the mesothelium. However, the detailed molecular
mechanisms that drive the formation of the mesothelium have not been described yet,
neither in the mouse nor in other vertebrate model organisms.
Molecular Markers
There is only limited evidence of the expression of specific molecular markers during
the early stages of mesothelial development. The earliest specific mesothelial marker
expressed from around E9.0 onwards is the Wilms’ tumour protein, WT1 [103,104]. The
mammalian Wt1 gene gives rise to at least 36 potential isoforms and these have roles in
transcriptional regulation of mesenchymal-epithelial transition and mesenchymal mainte-
nance in kidney development, and epithelial-mesenchymal transition and the regulation of
mesenchymal progeny from mesothelial tissues, including the heart, liver, lungs and intes-
tine [105,106]. Lineage tracing studies have demonstrated that WT1-expressing mesothelial
cells contribute during embryonic development to lung mesenchyme [107–109], cardiomy-
ocytes and coronary vessels in the heart [108,110,111], hepatic stellate and perivascular
cells [112,113], pancreatic stellate cells [114,115], and intestinal vascular and visceral smooth
muscle [104,116], as well as mesenteric fat [117]. Especially in the developing epicardium,
it has been well established that WT1 controls transition towards mesenchymal cell types
via transcriptional regulation of Snail and E-cadherin expression [118]. Similarly, WT1 con-
trols EMT in the embryonic epicardium by regulation of Wnt and retinoic acid signalling
pathways [119].
WT1 continues to be expressed in the peritoneal and visceral mesothelium into adult-
hood [104,115]. In the adult mouse peritoneum, WT1 expression has been reported in a
defined population of submesothelial cells [64,120]; however, the cell lineage and molecular
processes giving rise to submesothelial cells remain obscure. It is important to note that
WT1 expression in mesothelial cells is not uniform [65,115], and levels of WT1 expression
are reduced in the adult epicardium and lung and liver mesothelium when compared to
embryonic stages [121]. Genetic lineage tracing in the adult mouse have shown that in
normal tissue homeostasis and when compared to the embryo, WT1-expressing mesothelial
cells do not contribute to the mesenchymal cell types in the lung, heart, liver, and intes-
tine [109,110]. However, one caveat of the adult WT1-based mesothelial lineage systems is
the observation that they label less than 100% of the mesothelial cells [32,64]. Inactivation
of WT1 in the embryo results in lethality due to renal agenesis since WT1 is a dominant
regulator of kidney development [122] and also affects the heart, liver, pancreas, and
septum transversum [123,124], while adult ablation of WT1 leads to multi-organ failure,
affecting the kidneys, haematopoiesis, bone, visceral fat, pancreas, and heart [115,117].
Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)–linked cell-surface glyco-
protein which is expressed in developing and adult mesothelium [30,125,126]. It is not
known when MSLN starts to be expressed in the developing mesothelium; however, the
Eurexpress mouse embryonic expression atlas demonstrates Msln RNA expression at E14.5
in the epicardium and pericardium, as well as diaphragm, visceral mesothelium of the
intestinal tract, liver, and bladder but also in smooth muscle components [125]. Using a
MSLN-based lineage tracing system, mesothelium was shown to contribute to both visceral
and vascular smooth muscle and other mesenchymal components of visceral organs, both
during embryonic development but also postnatally [31], suggesting that adult MSLN-
lineage labelled mesothelium gives rise to a whole range of fibroblasts and smooth muscle
cells in the connective and adventitial tissues of organs housed within the serosal cavities.
The significance of MSLN expression for mesothelial functions is unknown since MSLN
knockout mice grow and reproduce normally and have no detectable mesothelium-related
phenotype [127].
Podoplanin (PDPN) is a transmembrane sialoglycoprotein with mucin-like charac-
teristics, which is found in mesothelia of the epicardium, peritoneum, and liver. Besides
expression in mesothelial tissues, PDPN is best known for its presence on lymphatic en-
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dothelial cells and in the podocytes of the kidneys [128]. PDPN fulfils its perhaps most
critical role via binding to the C-type lectin receptor CLEC-2 and subsequent regulation of
platelet aggregation and activation [129]. From E10.5 onwards in the mouse, PDPN was
detected in the mesothelial linings of the pericardial region, specifically the epicardium
and the pericardio–peritoneal canal but also cardiac mesenchyme that differentiates into
myocardium; this expression was maintained at later stages in the pericardial and pleural
mesothelial lining [130–132]. In the E12.5 mouse embryo, PDPN was detected in the liver
mesothelium where it was co-expressed with WT1 [112]. In the adult mouse, PDPN ex-
pression is maintained in the epicardium and peritoneal and liver mesothelium [32,126].
Interestingly, a mesothelial phenotype has not been reported after functional loss of PDPN
in mice [133,134].
The four-transmembrane glycoprotein m6a (GPM6A) plays an important role in
neuronal growth cones [135]. GPM6A was identified as a mesothelial marker in E12.5
PDPN+ liver mesothelium [67] and has subsequently been described in adult mouse liver
and peritoneal mesothelium [32,67]. GPM6A-based lineage studies have not been reported,
while the GPM6A knockout in mice demonstrated no mesothelial phenotype [136].
The uroplakin 3b (Upk3b) gene encodes a protein with a single transmembrane domain
with glycosylated N-terminus at the apical side, which was found to be expressed in
mesothelia of the heart, lung, liver, and intestine [30]. Detailed embryonic expression
analysis revealed that Upk3b transcripts are found in the developing visceral and parietal
mesothelium of the peritoneal cavity and in the pro-epicardial organ of the heart and
pericardium in the E9.5 mouse embryo [137]. In subsequent embryonic stages, UPK3B
expression consolidates in the mesothelial layers of all serosal cavities. The urothelium,
which forms from around E14.5 onwards, also expressed UPK3B. Analysis of loss of
UPK3B in a knockout mouse line (Upk3bCreERT2/+) demonstrated no obvious phenotype in
the mesothelial tissues nor in the bladder and ureter [137]. The Upk3bCreERT2/+ mouse line
and recently generated transgenic mice carrying a Cre cassette under control of the mouse
Upk3b gene (Tg(Upk3b-Cre)) have not been found to be suitable for genetic lineage tracing
studies of the mesothelium or urothelium [137,138].
Additional markers identified as specifically expressed in the mesothelium or epi-
cardium and co-expressed with some of the proteins discussed above include Podocalyxin,
Cytokeratin 5/6, ALCAM, Desmin, Ezrin, CD200, HBME-1 (rat and human), UPK1, LRRN4,
MUC16, TBX18, and intercellular adhesion molecule 1 (ICAM1) [30,65,139–141]. However,
it is unknown whether mesothelial cells at the different anatomical positions, and through-
out all developmental stages and in the healthy adult, uniformly express all these markers.
It has also been questioned whether the various mesothelial cell subsets found share a
common embryonic origin or actually represent individual mesothelial cell subtypes [98].
Of note, single cell RNA seq analysis of human peritoneum identified WT1, PDPN, MSLN,
UPK3B, LRRN4, GPM6A, ICAM1, cytokeratins, and calbindin 2 as mesothelial-specific
genes [142].
The expression and function of the main mesothelial molecular markers are sum-
marised in Table 1.
Table 1. Expression and function of mesothelial molecular markers during development.
Gene Name, Molecule
Type
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4. Further Discussion and Areas of Future Research
To better understand the key cellular and molecular mechanisms that contribute
to adhesion formation, there needs to be a clearer knowledge of the contribution and
source of peritoneal cells in development, homeostasis, and repair. Although many studies
have focused on characterising these cells and determining their role post-surgery, includ-
ing lineage tracing approaches, the wide range of injury stimuli applied in the various
experimental model systems is likely to affect the way peritoneal cells respond. Such
heterogeneity could explain some of the disparities in the expression of cell markers and
hence in findings reported between different studies. Furthermore, certain marker panels
may fail to identify all of a particular cell type and their destinations reliably.
Mesothelial cells have also been isolated from adherent or free-floating ascites, lavage,
and exudate sources and often also cultured; as such, these cells as well as subserosal
cells have been shown to possess multiple properties [143–145]. However, it is not clear
whether free-floating cells are the same as adherent cells, if contaminated mesothelial cell
populations have been isolated due to lack of additional purification steps or whether
selection pressures during culture have influenced the cell population analysed and/or its
phenotype. Mesothelial cell markers documented during embryonic development may
not be consistent with those in the adult, or there may be a reactivation of developmental
processes and hence the same markers re-emerge after peritoneal injury in the adult.
Most lineage tracing experiments are performed in mice, so it remains to be clarified if
these markers are the same as those found in humans. Both animal and human studies
have to a certain extent been hampered by the lack of mesothelial cell specific antibody
probes capable of positively identifying mesothelial cells while avoiding contamination
with other cells. Clearly further research is needed to clarify the repertoire of markers
expressed by different populations of peritoneal cells during development, homeostasis,
and post-surgery, in both mice and humans.
Peritoneum covering different tissue and organs may have distinctive characteristics
and respond in a particular manner to injurious stimuli. It is proposed that different sub-
populations of mesothelial cells and subserosal fibroblasts exist that show varying degrees
of marker expression [67,92]. It has been found that liver mesothelial cells change pheno-
type differently compared with cavity wall mesothelium after repeated chemically-induced
injury [32]. Peritoneal fibrosis and mass adhesion formation associated with encapsulating
peritoneal sclerosis (EPS), a rare but severe consequence of long-term peritoneal dialysis,
is predominately localised to the visceral rather than parietal peritoneum and in mice,
heterogeneity has been found between the two populations when cells were isolated and
analysed in vitro for gene expression and motility [146]. Local microenvironmental fac-
tors may influence molecular expression and cell behaviour in different areas of adult
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peritoneum. For instance, mesothelial cells on the surface of the ovary, also known as
ovarian epithelial cells (OECs), are proposed to be different from mesothelium on the rest
of peritoneum. Specifically, they have been found to be relatively uncommitted pluripo-
tential cells reflected through a different growth potential, capacity to change phenotype
in response to environmental stimuli, and an ability to differentiate along several path-
ways [147]. Whether they have adopted to this phenotype in order to perform the function
of continuous re-epithelialisation following cyclical ovulation remains to be explored. In
addition, subpopulations of WT1-positive mesothelial cells and subserosal fibroblasts in the
omentum, a vascularised adipose-rich peritoneal fold, have been found to be particularly
high producers of retinoic acid. Importantly, retinoic acid is implicated in the homeostasis
of cavity GATA6+ macrophages [120,148]. It is interesting to speculate whether dysregula-
tion of this process is part of the reason for a higher incidence of adhesions reported in obese
patients [85]. Furthermore, omentectomy in rabbits results in a greater prevalence of intesti-
nal adhesions after surgery in particular in the presence of infection or mesh implant [149].
Hence it is proposed that the omentum acts as a protective mechanical barrier prevent-
ing the formation of detrimental adhesions. However, by characterising mesenchymal
cells isolated from experimental omental adhesions, Gomez-Gil and colleagues found that
their phenotype and behaviour in culture related to type of adhesions they formed, either
adipose rich and highly vascularised or fibrous and populated with myofibroblasts [150].
Local environmental factors such as inflammation, infection, ischaemia, and mechanical
stress as well as metabolic status likely determine the type of omental adhesions induced
to form post-surgery [151]. Interestingly, injured mesothelium is able to signal to uninjured
adjacent mesothelium causing a reciprocal change in cell phenotype and behaviour [152].
In addition, calcium-dependent induction of cell membrane protrusions has been found to
mediate extensive connections between mesothelial cells that acts as a trigger for adhesion
formation [153]. Therefore, it will also be important to explore the influence of such local
environmental factors within the peritoneum as a whole.
Adhesion formation and its consequences remains a huge economic and health-
related burden following abdominal/pelvic surgery. Moreover, it is envisaged that this
problem is on the rise due to a growing ageing population and wider acceptance of
certain abdominal/pelvic surgical practices globally. However, new treatments to prevent
or limit adhesion formation have not been forthcoming to the clinic. Recent advances
have uncovered a greater complexity of the peritoneum than previously recognised and
so it may be timely to readdress some of the conventional thinking and bring together
disparate specialities with a common interest in peritoneal biology. By doing so, a more
comprehensive understanding of adhesion formation will be developed resulting in the
generation of better therapeutic strategies.
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